Home>Video>Shire Gains New Pinkeye Treatment With Deal For Eye-Drug Firm

Shire Gains New Pinkeye Treatment With Deal For Eye-Drug Firm

Mon, 3 Aug 2015

Shire Gains New Pinkeye Treatment With Deal For Eye-Drug Firm

  1. Related Videos
  2. Related Articles
  3. Comments
  1. Answering ETF Concerns

    Vanguard principal and ETF strategist Joel Dickson responds to worries that increased passive investing has led to more market volatility and that ETFs cause investors to gamble with their portfolios.

  2. Three Things to Watch Following Vanguard's Index Swap

    Investors should keep tabs on a few key indicators as Vanguard switches the benchmarks for 22 of its index funds.

  3. Out of Equities and Into the Fire?

    Although investors may remain broadly skeptical of equity markets, asset flow data suggest they could be taking more risk than expected in other asset classes.

  4. Sauter: Cost Certainty Key With New Benchmarks

    Vanguard's CIO says the fund shop is looking forward to the substantial long-term cost savings and price stability once it transitions to the FTSE and CRSP indexes, beginning next year.

  5. Behind Vanguard's Surprising China Decision

    Is it out of character for the normally conservative fund firm to add volatile China A-shares to its Emerging Markets Index Fund ?

  6. Why Vanguard Was Hard to Beat in 2014

    It was tough for active managers to outpace Vanguard's low-cost index funds in 2014, and many of its active funds also outperformed.

  7. Investors Flock to Foreign-Stock and Noncore Bond Funds

    As rising rates and emerging markets lose momentum, fund investors are eyeing nontraditional fixed-income categories and European and Japanese equities.

  8. Get the Best Out of Active and Index Funds

    In this 60-minute roundtable report, Morningstar's Russ Kinnel, Ben Johnson, John Rekenthaler, and Christine Benz dissect indexing's popularity, index versus active fund performance, and how investors can effectively blend the best of both in a portfolio.

blog comments powered by Disqus
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.